SEC Form 4 · accession 0001104659-17-038154
T2 Biosystems, Inc. · TTOO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Terrence Gibbs
Officer — General Counsel
Period of report
Jun 6, 2017
Accepted (ET)
Jun 8, 2017 · 4:15 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001492674
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jun 6, 2017 | P | 1,000 | $3.51 | A | 10,431 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported is a weighted average price. The shares were purchased in multiple transactions at per share price ranging from $3.50 to $3.52. The reporting person undertakes to provide upon request the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2Includes 9,331 shares acquired shares acquired under the Issuer's employee stock purchase plan between November 15, 2015 and May 15, 2017.